| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | MDDase; MPD; Mvd;;MVD |
| WB Predicted band size | 43 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | A synthesized peptide derived from human MVD |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是关于MVD(可能涉及不同领域，如代谢酶、微血管病或MOG抗体相关疾病)的参考文献示例。由于“MVD抗体”的术语可能存在多义性，以下内容基于常见研究方向整理：
---
1. **文献名称**：*Autoantibodies to MOG in adults with inflammatory demyelinating disease*
**作者**：Reindl M, et al.
**摘要**：研究探讨了抗髓鞘少突胶质细胞糖蛋白(MOG)抗体在成人炎性脱髓鞘疾病(如多发性硬化、视神经脊髓炎)中的诊断价值，提出MOG抗体可作为区分不同亚型疾病的生物标志物。
2. **文献名称**：*Anti-ADAMTS13 autoantibodies in thrombotic microangiopathies*
**作者**：Fujimura Y, et al.
**摘要**：分析血栓性微血管病(TMA)患者中抗ADAMTS13抗体的作用，揭示其通过抑制ADAMTS13酶活性导致血小板异常聚集，进而引发微血管血栓形成的机制。
3. **文献名称**：*Mevalonate kinase deficiency: Role of autoantibodies in disease pathogenesis*
**作者**：Hoffmann GF, et al.
**摘要**：探讨甲羟戊酸激酶(MVK)缺乏症(一种遗传性代谢病)患者中自身抗体的潜在影响，提出代谢紊乱可能诱发继发性自身免疫反应。
4. **文献名称**：*Biomarkers in MOG antibody-associated disease: A systematic review*
**作者**：Jarius S, et al.
**摘要**：系统综述了MOG抗体相关疾病的临床特征及抗体检测方法，强调其在儿童和成人中的不同临床表现及治疗反应差异。
---
**说明**：
- 若“MVD抗体”指代其他特定靶点(如肿瘤或感染相关抗原)，建议进一步明确术语背景以提供更精准的文献。
- 上述文献方向涵盖神经免疫(MOG抗体)、代谢疾病(MVK)和微血管病(ADAMTS13抗体)，均与可能的“MVD抗体”相关场景相关。
MVD (mevalonate diphosphate decarboxylase) is a key enzyme in the mevalonate pathway, a metabolic route critical for synthesizing cholesterol, isoprenoids, and other essential biomolecules. It catalyzes the ATP-dependent decarboxylation of mevalonate-5-diphosphate (MVDP) to isopentenyl diphosphate (IPP), a precursor for sterols and non-sterol isoprenoids. This pathway is conserved across eukaryotes and some bacteria, highlighting its biological significance. Dysregulation of the mevalonate pathway is linked to metabolic disorders, cardiovascular diseases, and cancers, particularly those driven by RAS oncogenes that depend on isoprenylation for signaling.
Antibodies targeting MVD are valuable tools for studying its expression, localization, and function in both physiological and pathological contexts. They enable detection of MVD protein levels via techniques like Western blotting, immunohistochemistry, or immunofluorescence, aiding research into metabolic adaptations in tumors or cholesterol-related conditions. Additionally, MVD inhibitors are explored as therapeutic agents, especially in cancers resistant to statins (which target upstream enzymes). Anti-MVD antibodies may also help validate inhibitor efficacy or identify biomarker signatures. Recent studies emphasize MVD's role in immune regulation and ferroptosis, expanding its relevance to autoimmune diseases and cancer immunotherapy. However, MVD's functional complexity—spanning metabolism, cell survival, and post-translational modification—warrants cautious interpretation of antibody-based assays to avoid cross-reactivity with homologous enzymes.
×
